2023
Mutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment options
2021
Therapeutic Advances in Small Cell Lung Cancer Management
Newton B, Chiang A. Therapeutic Advances in Small Cell Lung Cancer Management. Current Cancer Research 2021, 175-195. DOI: 10.1007/978-3-030-74028-3_8.Peer-Reviewed Original ResearchSmall cell lung cancer managementSmall cell lung cancer treatmentSmall cell lung cancerCell lung cancer managementCell lung cancer treatmentLung cancer managementCell lung cancerLung cancer treatmentRecalcitrant malignancySignificant management challengesLung cancerTherapeutic advancesCancer managementTherapeutic interventionsCancer treatmentNew targetsCell cycle regulationCycle regulationImmunotherapyMalignancyCancerDiseasePhysicians
2020
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade
Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K, Redrado M, Remírez A, Lecanda F, Alignani D, Lasarte J, Macaya I, Senent Y, Bértolo C, Sainz C, Gil-Bazo I, Eguren-Santamaría I, Lopez-Picazo J, Gonzalez A, Perez-Gracia J, de Andrea C, Vicent S, Sanmamed M, Montuenga L, Pio R. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nature Cancer 2020, 1: 75-85. PMID: 35121837, DOI: 10.1038/s43018-019-0007-9.Peer-Reviewed Original ResearchConceptsPD-1 blockadeCell death protein 1 (PD-1) pathwayPD-1 immune checkpoint blockadeCD8/Treg ratioHigh IGF-1R expressionInsulin-like growth factor-1Cell lung cancer treatmentIGF-1 levelsPD-1 inhibitionImmune checkpoint blockadeTumor-specific immunityCell lung cancerIGF-1R expressionHigher plasma levelsLung cancer progressionLung cancer treatmentIGF-1 receptorGrowth factor-1Protein 1 pathwayTreg ratioCD8 cellsCheckpoint blockadePD-1Syngeneic modelLung cancer
2017
Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice
Rosenberg SA, Baschnagel AM, Bagley SJ, Housri N. Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice. Current Oncology Reports 2017, 19: 5. PMID: 28168606, DOI: 10.1007/s11912-017-0563-z.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentLung cancer treatmentNational clinical trialEvidence-based treatmentsEvidence-based medicineTranslating EvidenceCommunity oncologistsBody radiotherapyLung cancerClinical trialsPreclinical discoveryClinical practiceCommunity settingsCancer treatmentOncologistsCommunity practiceTreatmentMedicineImmunotherapyNSCLCInternet-based resourcesRadiotherapyCancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply